Cited by — Real-world Outcomes of First-line Enfortumab Vedotin Plus Pembrolizumab in Elderly Patients With Advanced Urothelial Carcinoma | ResearchHub - ResearchHub
Research graph
Cited by
Admitted local publications that cite Real-world Outcomes of First-line Enfortumab Vedotin Plus Pembrolizumab in Elderly Patients With Advanced Urothelial Carcinoma.
No admitted local citation edges point to this work yet.
